1 / 22

Decision making: managing risk

Decision making: managing risk. Summary of an ISoP workshop, Berlin, 2004. ICH E2E. Risk Management Plan When a new drug is launched, what do you need to do to find out about, and minimise, risks Also for new, major risks. New Regulatory approach!. General overview.

gilles
Download Presentation

Decision making: managing risk

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Decision making: managing risk Summary of an ISoP workshop, Berlin, 2004

  2. ICH E2E • Risk Management Plan • When a new drug is launched, what do you need to do to find out about, and minimise, risks • Also for new, major risks New Regulatory approach!

  3. General overview • Define risk, or potential for a risk for a product • What type of decision is needed • Best data and information for the job • Patient safety and preventability • Expansion of pharmacovigilance • Communication is a major area of consideration

  4. Eliminating risk (not possible!) • Risk specification • Risk plan • Milestones • Risk minimisation • Start early and continue • High potency, high risk products • Tripartite involvement: • Prescriber • Dispenser • Patient

  5. What kind of decision? • To communicate a new risk • To add information which will aid prescribers in: • Avoiding risk • The early diagnosis of harm • The management of harm that has occurred • To alter the overall availability of the product

  6. What kind of decision? • Amending SPC requires: • Prescriber-useful information • Good communication practice • Follow up • Avoiding regulatory control may require comparative effectiveness-risk assessment

  7. Decision theory • Context • Anticipation • Definition • Simplification • Investigation • Data & information • Summation • Communication /Action • Follow up • Impact • Revision

  8. Anticipating risks • Pro-activity • Continuity • Science based evaluation in addition to spontaneous reports • Multidisciplinary • Consider costs & resources • Feasability & opportunity • MAH image • Win-win.

  9. Anticipating risks • Risk management plan started in early clinical development • Pre-clinical data • Class effects • Natural history of indication & co-morbidity • Consider reasons for extra safety studies (Predict ‘real life’) • Need for multiple methods • Need for better data sources • Risk groups e.g. children, pregnancy, elderly • Anticipate off label use: paediatrics • Special drugs • Orphan drugs, NCEs

  10. Anticipating risks • Conditional approval based on risk management plan • Should not lead to poorer pre-marketing standards • Management of studies? • Joint MAH & RA ? • Academia and professional bodies • Funding • Public? • Joint? • Periodic refreshing of plan

  11. Anticipating risks • Need for definitions of terms and criteria relating to risk management and planning etc. • Legal issues of compliance • Co-responsibility • Who decides protocols? • Use diversity • Transparency, ethical and data protection issues

  12. Investigating emerging risks • Multidimensional challenge • Factors effecting tool • Life cycle (rarity of event; extent of use) • Complexity of ADR (terminology issues, definitions, diagnosis v. signs and symptoms ) • Requirements for data source • Signal • Consolidation • Confirmation (time constraint) • Choose best tool (described) • Effectiveness-risk communication • Impact

  13. Investigating emerging risks • What to focus on and communicate • ‘Useful to clinician ‘ • What will affect patients’ choice • Preventability. • ADR diagnosis • ADR management • change in effectiveness • Interactions/additive/negative effects • Seriousness and severity issues • Quality of information • Clarity of clinical/epidemiological situation

  14. Warning and communication of risk • SPC • Use of PSUR • Legal v. Communication • Which section of SPC • Contra indication, warning • When changed? • Design ? • ‘Dear Health Professional‘ communication • Web • Design • Repeated • Media • Bulletins

  15. Warning and communication of risk • Considerable legal framework and guidelines • Governs what happens between players • Particularly reporting • Accuracy of information • Timing important • Start early? • Limitation on communicating between industry and HPs and public • Communication within company • Structure and responsibility (personal!) • ‘Communications’ v. ‘advertising’ • Responsibility of journals

  16. Warning and communication of risk • Players may have competing interests in communication even if public health is a common aim • Personnel skills • Independent • Cope with divergent aims • Cope with uncertainty • Communication and action

  17. Warning and communication of risk • Media • Dramatic news a priority • Internet • No control • When to communicate • Pro-activity • Know media • Call for vigilance • During effectiveness/risk evaluation • Crisis (out of control, reactive) • Rapid response is different • Provoked by third party communication

  18. Warning and communication of risk • What to communicate • Rare but important • Frequent, relevant • Important negative info. • Serious quality problems • Information on imminent products

  19. Warning and communication of risk • To whom • MAH and RA • H Ps • Patient organisations • Public • Social security • Analysts & stock exchange? • By whom • Must be competent communicator • Familiar with issues

  20. Warning and communication of risk • Wide range of issues possible • Difficult to predict response • Prepare for rapid and intense communication • HPs before public! • Communicating uncertainty • ‘Dialogue in Pharmacovigilance’

  21. Warning and communication of risk • Outcomes • Follow up? • Questionnaires • General • Count responses? • Need more information on outcomes • Better public education • Less paternalism • Better view of us! • Openness • Constructive law & media interaction

  22. Warning and communication of risk • A hierarchy of evidence based medicine in pharmacovigilance • Signal • Hypothesis • Controlled studies • Get to stronger evidence • Information • Knowledge detection • UMC and IMS • andrew.bate@who-umc.org • Wisdom • YOU

More Related